(2S)-2-[(tert-butoxycarbonyl)amino]-3-(5-fluoro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propyl 3-nitrobenzenesulfonate | 857264-74-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2S)-2-[(tert-butoxycarbonyl)amino]-3-(5-fluoro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propyl 3-nitrobenzenesulfonate
• 英文别名: [(2S)-3-(5-fluorospiro[3H-1-benzofuran-2,4'-piperidine]-1'-yl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propyl] 3-nitrobenzenesulfonate
• CAS: 857264-74-5
• 化学式: C₂₆H₃₂FN₃O₈S
• 分子量: 565.62
• InChiKey: VVBRBOSRLXRBQW-FQEVSTJZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  39
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  148
• 氢给体数：
  1
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  (2S)-2-[(tert-butoxycarbonyl)amino]-3-(5-fluoro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propyl 3-nitrobenzenesulfonate 在 caesium carbonate 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 37.0h， 生成 8-{[(2S)-2-amino-3-(5-fluoro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propyl]oxy}quinolin-2(1H)-one
  参考文献：
  名称：

  Structure activity relationships of fused bicyclic and urea derivatives of spirocyclic compounds as potent CCR1 antagonists

  摘要：

  A series of fused bicyclic and urea derivatives of spirocyclic compounds were designed, synthesised and evaluated in vitro as potent CCR1 antagonists. In particular, 4 (7 nM), 44 (1.3 nM), 48 (0.89 nM) and 50 (0.63 nM) were the most potent hCCR1 antagonists in this series of compounds. Moreover, some of these substances demonstrated good rodent cross-over, especially 46 which exhibited very high rat CCR1 binding affinity with an IC50 value of 16 nM. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.11.062
• 作为产物：
  描述：

  (R)-N-叔丁氧羰基-3-碘代丙氨酸甲酯 在 锂硼氢 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 96.0h， 生成 (2S)-2-[(tert-butoxycarbonyl)amino]-3-(5-fluoro-1'H,3H-spiro[1-benzofuran-2,4'-piperidin]-1'-yl)propyl 3-nitrobenzenesulfonate
  参考文献：
  名称：

  Structure activity relationships of fused bicyclic and urea derivatives of spirocyclic compounds as potent CCR1 antagonists

  摘要：

  A series of fused bicyclic and urea derivatives of spirocyclic compounds were designed, synthesised and evaluated in vitro as potent CCR1 antagonists. In particular, 4 (7 nM), 44 (1.3 nM), 48 (0.89 nM) and 50 (0.63 nM) were the most potent hCCR1 antagonists in this series of compounds. Moreover, some of these substances demonstrated good rodent cross-over, especially 46 which exhibited very high rat CCR1 binding affinity with an IC50 value of 16 nM. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.11.062

文献信息

• [EN] NOVEL TRICYCLIC SPIRODERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY<br/>[FR] NOUVEAUX SPIRODERIVES TRICYCLIQUES EN TANT QUE MODULATEURS DE L'ACTIVITE DES RECEPTEURS DE CHIMIOKINES
  申请人：ASTRAZENECA AB

  公开号：WO2005061499A1

  公开（公告）日：2005-07-07

  The invention provides compounds of formula (I) wherein m, R1, n, R2, q, p, X, Y, R3, R4, t and, R5 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  这项发明提供了式（I）的化合物，其中m、R1、n、R2、q、p、X、Y、R3、R4、t和R5如规范中所定义，以及它们的制备方法、含有它们的药物组合物以及它们在治疗中的应用。
• Novel tricyclic spiroderivatives as modulators of chemokine receptor acitivity
  申请人：Hossain Nafizal

  公开号：US20070099945A1

  公开（公告）日：2007-05-03

  The invention provides compounds of formula (I) wherein m, R 1 , n, R 2 , q, p, X, Y, R 3 , R 4 , t and, R 5 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  该发明提供了式（I）的化合物，其中m，R1，n，R2，q，p，X，Y，R3，R4，t和R5如规范中定义，以及它们的制备方法，含有它们的制药组合物以及它们在治疗中的应用。
• Novel tricyclic spiroderivatives as modulators of chemokine receptor activity
  申请人：Hossain Nafizal

  公开号：US20090298861A1

  公开（公告）日：2009-12-03

  The invention provides compounds of formula (I) wherein m, R 1 , n, R 2 , q, p, X, Y, R 3 , R 4 , t and, R 5 are as defined in the specification, processes for their preparation, pharmaceutical compositions contain them and their use in therapy.

  本发明提供了式(I)的化合物，其中m，R1，n，R2，q，p，X，Y，R3，R4，t和R5如规范中所定义，以及它们的制备方法，包含它们的制药组合物以及它们在治疗中的使用。
• NOVEL TRICYCLIC SPIRODERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
  申请人：AstraZeneca AB

  公开号：EP1699791A1

  公开（公告）日：2006-09-13
• US7524856B2
  申请人：——

  公开号：US7524856B2

  公开（公告）日：2009-04-28